The expansion of KIR2DL1+ CD8+ T cells induced by its specific C2-ligand was observed in all cancer patients (2.21% vs. 0.94%, p < 0.01, compared to patients without the C2-ligand) and maintained in patients who survived the monitoring period(2.45% vs. 0.86%, p < 0.01), but abrogated in patients who died during the follow-up (0.62% vs. 0.61%) (Figure 2A). The gene discussed is CD8A; the disease is cancer.